Caplacizumab (Cablivi®). HTA ID: 22013

Assessment Status Rapid Review complete
HTA ID 22013
Drug Caplacizumab
Brand Cablivi®
Indication Treatment of adults and adolescents aged 12 years and older weighing at least 40 kg experiencing an episode of acquired thrombotic thrombocytopenic purpura (aTTP), in conjunction with plasma exchange and immunosuppression.
Assessment Process
Rapid review commissioned 07/03/2022
Rapid review completed 31/03/2022
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of caplacizumab compared with the current standard of care.